Rachel M. Smith

Rachel M. Smith

Auto-generated profile, based on publicly available information

Rachel M. Smith

Center for Biostatistics, College of Medicine, The Ohio State University, Columbus, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
JSJustin D. Singleton
Justin D. Singleton
RDReuben Dass
Reuben Dass
NNNathaniel R. Neubert
Nathaniel R. Neubert
RSRachel M. Smith
Rachel M. Smith
ZWZak Webber
Zak Webber
MPMatt A. Peterson
Matt A. Peterson

13 December 2022 in Paediatric and Perinatal Epidemiology
Verified
Journal Article
Open access
CLCourtney D. Lynch
Courtney D. Lynch
SCSara Conroy
Sara Conroy
KJKenneth A. Jackson
Kenneth A. Jackson
RSRachel M. Smith
Rachel M. Smith
EHErinn M. Hade
Erinn M. Hade
Background: Lack of access to reliable transportation is a barrier to timely receipt of prenatal care.Objectives: We aimed to assess the impact of modernisation of non‐emergency medical transportation services on patient satisfaction, prenatal care utilisation, and preterm delivery.Methods: We conducted a randomised controlled pilot trial among pregnant Medicaid recipients in Franklin County, Ohio, a county with high rates of infant mortality. Individuals were randomly assigned to usual non‐emergency medical transportation services or enhanced smart transportation (EST) services (i.e. on‐demand transportation with access to a mobile application and trips to the grocery store, food bank or pharmacy). The primary outcome was satisfaction with transportation services. Secondary outcomes included adequacy of prenatal care utilisation (APNCU) and preterm delivery <37 weeks.Results: Women were screened between 31 May 2019 and 30 June 2020, with 143 being eligible and enrolling. Evidence of increased satisfaction with transportation was observed in the intervention group compared to usual transportation, with 83.8% and 68.8% reporting being somewhat satisfied or very satisfied respectively (risk difference [RD] 14.8%, 95% confidence interval [CI] 0.5, 29.1). There were no meaningful differences in APNCU or preterm delivery between groups (APNCU: RD 2.1%, 95% CI −14.0, 18.2 and preterm delivery: RD −3.9%, 95% CI −17.0, 9.3).Conclusions: We found evidence of increased transportation satisfaction among pregnant women randomly assigned to EST versus usual transportation. It remains unclear whether the provision of EST increases prenatal care utilisation or decreases preterm delivery.

18 May 2026 in Circulation
Verified
Journal Article
Open access
MNMichelle M.J. Nassal
Michelle M.J. Nassal
RSRachel M. Smith
Rachel M. Smith
EAElisabete Aramendi
Elisabete Aramendi
AEAndoni Elola
Andoni Elola
XJXabier Jaureguibeitia
Xabier Jaureguibeitia
HWHenry Wang
Henry Wang
BACKGROUND: Exhaled end-tidal carbon dioxide (EtCO 2 ) trajectory is associated with out-of-hospital cardiac arrest (OHCA) outcomes. However, the minimum EtCO 2 monitoring duration needed to discriminate return of spontaneous circulation (ROSC) from non-ROSC remains unknown. We sought to determine the EtCO 2 trajectory observation time required to differentiate ROSC from non-ROSC patients. METHODS: We performed a secondary analysis of the cluster-randomized Pragmatic Airway Resuscitation Trial (PART), which assessed endotracheal intubation or laryngeal tube strategies in OHCA resuscitation. We summarized mean EtCO 2 in 1-minute epochs over the resuscitation. Cases were stratified a priori by: (1) witnessed versus unwitnessed status, and (2) initial EtCO 2 : low (≤30 mm Hg), moderate (31–49), and high (≥50). Within each stratum, group-based trajectory modeling (GBTM) was used to identify latent EtCO 2 trajectory classes, and patients were categorized into an upward or downward trajectory. To balance trajectory groups on baseline characteristics including age, sex, race, initial rhythm, location, and bystander CPR, we applied inverse probability of treatment weighting. We fit weighted pooled logistic regression models to estimate risk ratios (RRs) for ROSC comparing upward versus downward EtCO 2 trajectories. Within each stratum, we identified the earliest minute when CIs between upward versus downward EtCO 2 trajectories no longer overlapped. RESULTS: EtCO 2 data were available for 1168 patients: 452 (38.6%) witnessed and 716 (61.1%) unwitnessed. Patients were predominantly men (63.5%), with a median age of 65 years (Q1, Q3: 53–75), majority White race (51.3%), and presenting in a nonpublic setting (85.4%). Overall ROSC was 18.2%: 30.5% of witnessed and 10.5% of unwitnessed. Among witnessed arrests, 95% CI for upward versus downward EtCO 2 trajectories no longer overlapped at 8 minutes for low initial EtCO 2 (RR, 3.06; 95% CI, 1.49, 6.71), 12 minutes for moderate EtCO 2 (RR, 1.95; 95% CI, 1.23, 3.48), and 21 minutes for high EtCO 2 (RR, 2.12; 95% CI, 1.30, 3.73). Among unwitnessed arrests, nonoverlapping CIs were first observed at 7 minutes (RR, 3.56; 95% CI, 1.53, 10.37). CONCLUSIONS: Depending on witness status and initial EtCO 2 , between 7 and 21 minutes of monitoring are needed to reliably differentiate upward from downward EtCO 2 trajectories during OHCA resuscitation. Dynamic EtCO 2 trajectory monitoring may provide early prognostic information to guide resuscitation.

24 June 2026 in Cancer Prevention Research
Verified
Journal Article
Closed access
LSLeigha Senter
Leigha Senter
SHShelly Hovick
Shelly Hovick
RNRachel Notestine
Rachel Notestine
LNLauren Norden
Lauren Norden
NBNadia Benny
Nadia Benny
ATAmanda Toland
Amanda Toland
Individuals with germline BRCA1 or BRCA2 pathogenic variants (PVs) may struggle with risk management decision-making. Advancements in technology could provide more specific risk information to patients, but the impact of this information is unknown. The Clinical Application of Refined Risk Estimates Study is a two-arm randomized controlled trial in women with a BRCA1/BRCA2 PV. The primary objective was to determine whether genotype-informed cancer risk estimates (GRE) compared to standard lifetime cancer risk estimates (SRE) decreased decisional conflict related to cancer risk management decision-making. Women were recruited following disclosure of their PV results. Participants completed a baseline survey and were randomized 1:1 to receive a GRE or SRE. After receiving their results, participants completed a follow-up survey. Likert and continuous data measures were analyzed using linear regression. There were no differences in decisional conflict between study arms at follow-up. However, individuals in the SRE arm showed an increased need for personal structure compared to those in the GRE arm (p =0.02). Compared to baseline, individuals within the SRE arm showed decreased decisional conflict (p =0.003) and increased perceived stress (p =0.02) at follow-up. A more personalized cancer risk estimate did not decrease decisional conflict in women with BRCA1/BRCA2 PVs. Future studies will determine whether a GRE impacts actual decision-making behaviors.

8 July 2026 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
YCYijie Cheng
Yijie Cheng
JGJoshua W. Gaborcik
Joshua W. Gaborcik
RSRachel M. Smith
Rachel M. Smith
KDKathleen Dungan
Kathleen Dungan
ASAndrew C. Stone
Andrew C. Stone
Background: Insulin is commonly used to manage steroid-induced hyperglycemia. However, optimal dosing strategies for long-acting steroids like dexamethasone remain unclear. Objectives: This study evaluated insulin glargine use for dexamethasone-induced hyperglycemia (DIH) and evaluated factors associated with achieving glucose targets (AGTs). Methods: This retrospective, single-centered cohort study included adult, noncritically ill patients who received once-daily insulin glargine and dexamethasone for at least 3 consecutive days during admissions between July 1, 2021, and July 31, 2023. Patients were excluded if they had type 1 diabetes mellitus or received intravenous insulin within the first 3 days. The primary outcome was the percentage of patients AGT, defined as mean blood glucose 70 to 180 mg/dL on day 3 of combination therapy. Patients were then stratified into AGT and persistent hyperglycemia (PH) cohorts to evaluate secondary outcomes which included hypoglycemia incidence and patient or treatment characteristics associated with AGT. Results: Among 118 patients included, 28 (24%) were in the AGT cohort and 90 (76%) were in the PH cohort. The AGT cohort had a lower mean body mass index (29.1 vs 33.7 kg/m 2 , P = .02) and fewer patients with preexisting type 2 diabetes mellitus (85.7% vs 97.8%, P = .03). Median insulin glargine units standardized by dexamethasone dose was similar between cohorts (2.25 [1.08-3.33] vs 2.00 [1.17-4.00] units/mg/day, P = .98). The PH cohort required significantly higher median daily bolus insulin doses (24 vs 6 units/day, P < .01). There was 1 patient, who was in the AGT cohort, who experienced hypoglycemia. Conclusion and Relevance: This study suggests that current practice underdoses insulin glargine initially for DIH management and relies on reactive bolus insulin with limited success. Earlier and more assertive insulin glargine dosing is warranted to improve early glycemic control without substantially increasing hypoglycemia risk. Limitations include the retrospective single-centered study design and limited sample size with imbalanced cohorts.

25 December 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
KBKasey M Belanger‐Mayer
Kasey M Belanger‐Mayer
RSRachel Smith
Rachel Smith
KPKevin Pumiglia
Kevin Pumiglia
KZKristen L Zuloaga
Kristen L Zuloaga
Background: Over 80% of individuals with AD have a co‐morbid metabolic disease, defined as obesity, glucose intolerance, or diabetes. Both metabolic disease and a HF diet cause the release of inflammatory factors, increases AD risk, and alters the expression of hippocampal microvascular genes. Work has increased in identifying specific networks and the genes that drive these networks in AD. We hypothesize that AD causes baseline changes in a specific cluster of genes and when a HF diet is introduced, it further drives alterations of a sub‐population of genes to drive the worsening of AD pathology.Method: Male wild type (WT) and AppNL‐F knock‐in mice were given a low fat (LF; 10% fat) or high fat (HF; 60% fat; metabolic disease model) diet for 1 month. Weekly weights and end of study visceral fat weight were taken. The hippocampus was rapidly extracted and flash frozen for bulk RNA sequencing and differential gene expression analysis.Result: On an LF diet, AppNL‐F mice had a greater body weight gain and greater visceral fat compared to WT controls. HF diet increased body weight and visceral fat in WT mice. There was surprisingly no difference between AppNL‐F mice on a LF diet and HF diet in body weight gain and visceral fat. There were 760 significant hippocampal gene alterations between AD and WT mice. Within the WT controls on a LF vs HF diet, there were 213 gene alterations and within the AD model on a LF vs HF diet, there were 31 gene alterations.Conclusion: AppNL‐F mice on both a LF and HF diet gained equivalent amounts of weight, displaying an altered metabolic profile due to AD alone. While AD alone caused most of the gene alterations, a HF diet further drove alterations in a subset of genes. This work increases our understanding of the contribution of a HF diet to metabolic disease and alterations in AD‐risk associated hippocampal genes to uncover potential modifiable targets. We are currently examining specific clusters of genes and how they are linked to AD pathology, increased inflammation, and vascular dysfunction, and sequencing hippocampal samples from female mice to examine sex differences.